TrialInternational journal of chronic obstructive pulmonary disease

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.

Fabrizia Mariotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.